[go: up one dir, main page]

WO2003037266A3 - Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique - Google Patents

Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique Download PDF

Info

Publication number
WO2003037266A3
WO2003037266A3 PCT/US2002/034760 US0234760W WO03037266A3 WO 2003037266 A3 WO2003037266 A3 WO 2003037266A3 US 0234760 W US0234760 W US 0234760W WO 03037266 A3 WO03037266 A3 WO 03037266A3
Authority
WO
WIPO (PCT)
Prior art keywords
heptapeptides
hexa
penta
tetra
antiangiogenic activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/034760
Other languages
English (en)
Other versions
WO2003037266A2 (fr
Inventor
Fortuna Haviv
Michael F Bradley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/000,540 external-priority patent/US20030119745A1/en
Priority claimed from US10/000,711 external-priority patent/US20030105025A1/en
Priority claimed from US10/263,811 external-priority patent/US20030105022A1/en
Priority to CA002466152A priority Critical patent/CA2466152A1/fr
Priority to EP02789322A priority patent/EP1451209A4/fr
Priority to MXPA04004135A priority patent/MXPA04004135A/es
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to JP2003539612A priority patent/JP2005512980A/ja
Priority to AU2002353922A priority patent/AU2002353922A1/en
Publication of WO2003037266A2 publication Critical patent/WO2003037266A2/fr
Publication of WO2003037266A3 publication Critical patent/WO2003037266A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés représentés par la formule (SEQ ID NO: 2) et (SEQ ID NO: 3), qui sont utiles dans le traitement d'états engendrés ou exacerbés par l'angiogénèse. L'invention concerne également des compositions pharmaceutiques renfermant ces composés, des procédés de traitement utilisant ces composés, et des procédés permettant d'inhiber l'angiogénèse.
PCT/US2002/034760 2001-10-31 2002-10-30 Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique Ceased WO2003037266A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002353922A AU2002353922A1 (en) 2001-10-31 2002-10-30 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
JP2003539612A JP2005512980A (ja) 2001-10-31 2002-10-30 抗血管新生作用を有するテトラ−、ペンタ−、ヘキサ−及びヘプタペプチド
CA002466152A CA2466152A1 (fr) 2001-10-31 2002-10-30 Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique
EP02789322A EP1451209A4 (fr) 2001-10-31 2002-10-30 Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique
MXPA04004135A MXPA04004135A (es) 2001-10-31 2002-10-30 Tetra-, penta-, hexa y heptapeptidos con actividad antiangiogenica.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/000,540 US20030119745A1 (en) 2001-10-31 2001-10-31 HEXA- and heptapeptides having antiangiogenic activity
US10/000,007 2001-10-31
US10/000,540 2001-10-31
US10/000,711 US20030105025A1 (en) 2001-10-31 2001-10-31 Tri-and tetrapeptides having antiangiogenic activity
US10/263,811 2002-10-04
US10/263,811 US20030105022A1 (en) 2001-10-31 2002-10-04 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity

Publications (2)

Publication Number Publication Date
WO2003037266A2 WO2003037266A2 (fr) 2003-05-08
WO2003037266A3 true WO2003037266A3 (fr) 2003-12-11

Family

ID=32659830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/034760 Ceased WO2003037266A2 (fr) 2001-10-31 2002-10-30 Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique

Country Status (6)

Country Link
EP (1) EP1451209A4 (fr)
JP (1) JP2005512980A (fr)
CA (1) CA2466152A1 (fr)
MX (1) MXPA04004135A (fr)
UY (1) UY27523A1 (fr)
WO (1) WO2003037266A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125260A1 (en) * 2001-10-31 2003-07-03 Fortuna Haviv Tetra-and pentapeptides having antiangiogenic activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061476A1 (fr) * 1998-05-22 1999-12-02 Abbott Laboratories Medicaments peptidiques anti-angiogeniques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5932545A (en) * 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061476A1 (fr) * 1998-05-22 1999-12-02 Abbott Laboratories Medicaments peptidiques anti-angiogeniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1451209A4 *

Also Published As

Publication number Publication date
JP2005512980A (ja) 2005-05-12
EP1451209A4 (fr) 2009-06-03
EP1451209A2 (fr) 2004-09-01
CA2466152A1 (fr) 2003-05-08
MXPA04004135A (es) 2004-07-08
UY27523A1 (es) 2003-05-30
WO2003037266A2 (fr) 2003-05-08

Similar Documents

Publication Publication Date Title
CA2367017A1 (fr) Inhibiteurs de l'enzyme impdh
PL344861A1 (en) Trazinic angiogenesis inhibitiors
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2002076976A3 (fr) Inhibiteurs de rho-kinase
WO2002076977A3 (fr) Inhibiteurs de rho-kinase
DE60112609D1 (en) Pyrazolopyridine
BG106340A (en) Substituted oxoazaheterocyclyl compounds
WO2003000200A3 (fr) ss-2'-OU 3'-HALONUCLEOSIDES
WO2002064594A3 (fr) Pyrido-pyrimidines substituees en position 6
WO2004004657A3 (fr) Inhibiteurs de l'integrase du vih
GB0215293D0 (en) Viral inhibitors
WO1999054326A8 (fr) Dihydropyrimidines
WO2002100844A3 (fr) Inhibiteurs de la protease vih, compositions les contenant, leurs utilisations pharmaceutiques et materiaux utilises pour leur synthese
AU5242000A (en) Nematicidal trifluorobutenes
GB0011203D0 (en) Chemical compounds
DE60112330D1 (en) Pyrazolopyridinderivate
WO2001021164A3 (fr) Compositions anti-mycobacterium, procedes de preparation et d'utilisation associes
WO2003037912A3 (fr) Tripeptides, tetrapeptides et pentapeptides a activite anti-angiogenese
AP1766A (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation.
WO2003070204A3 (fr) Composition inhibitrice des lipases
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese
MXPA04000805A (es) Peptidos que tienen actividad antiangiogenica.
WO2004073375A3 (fr) Derives de podophyllotoxine utiles comme agents antitumoraux
WO2003037266A3 (fr) Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique
MXPA03000166A (es) Derivados de tirosina como inhibidores de fosfatasa.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003539612

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004135

Country of ref document: MX

Ref document number: 2466152

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002789322

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002789322

Country of ref document: EP